9.2399
price up icon1.76%   0.1599
 
loading

Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten

pulisher
Jun 18, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics (SAGE) for $8.50 Per Share - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
$20.39
price down icon 0.34%
$36.24
price down icon 0.27%
$23.15
price up icon 7.69%
$96.83
price down icon 0.40%
$108.13
price up icon 0.15%
biotechnology ONC
$247.47
price up icon 1.13%
Kapitalisierung:     |  Volumen (24h):